BMC cancer · 2026
Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Jingshuai, Yu Yuhui, Sun Yan, Chen Xiaofeng, Yan Caiwang, Sun Qiufen, Jin Guangfu
Аннотация
BACKGROUND: Current tissue-based biomarkers for gastric cancer (GC) immunotherapy face significant limitations due to tumor heterogeneity and sampling constraints. This study explores plasma proteome profiling as a non-invasive strategy to identify dynamic biomarkers predictive of treatment response.
METHODS: In a prospective cohort of 88 advanced GC patients receiving immunotherapy, we performed longitudinal plasma proteomic analysis at baseline and during cycles 2 and 4. Ridge regression was employed to develop composite protein scores, which were validated using Cox models and Kaplan-Meier analyses. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), as well as biomarker dynamics, were assessed over a median follow-up period of 12.9 months.
RESULTS: A baseline composite score integrating IFN-gamma, CSF-1, MIC-A/B, and ANGPT demonstrated superior discriminative power for immunotherapy response (area under the ROC curve [AUC]) = 0.77, 95% confidence intervals [CI]: 0.67-0.88) compared to individual markers. Elevated baseline levels of IFN-gamma correlated with prolonged PFS (upper median vs. lower median: Hazard ratios [HR] = 0.67, P = 0.007) and OS (HR = 0.64, P = 0.012). Longitudinal monitoring revealed the dynamics pattern of IFN-gamma: early elevation predicted durable clinical benefit (DCB) (median PFS: not evaluable vs. 6.7 months in no-durable benefit [NDB]), while a persistent decrease post-cycle 4 indicated a risk of relapse (P = 0.028).
CONCLUSION: IFN-gamma emerges as a critical biomarker for prognostic assessment and therapeutic monitoring in advanced GC immunotherapy, and its composite model incorporating PD-L1 Combined Positive Score (CPS) demonstrated superior predictive efficacy, highlighting the necessity for validating additional biomarkers in future clinical studies.
METHODS: In a prospective cohort of 88 advanced GC patients receiving immunotherapy, we performed longitudinal plasma proteomic analysis at baseline and during cycles 2 and 4. Ridge regression was employed to develop composite protein scores, which were validated using Cox models and Kaplan-Meier analyses. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), as well as biomarker dynamics, were assessed over a median follow-up period of 12.9 months.
RESULTS: A baseline composite score integrating IFN-gamma, CSF-1, MIC-A/B, and ANGPT demonstrated superior discriminative power for immunotherapy response (area under the ROC curve [AUC]) = 0.77, 95% confidence intervals [CI]: 0.67-0.88) compared to individual markers. Elevated baseline levels of IFN-gamma correlated with prolonged PFS (upper median vs. lower median: Hazard ratios [HR] = 0.67, P = 0.007) and OS (HR = 0.64, P = 0.012). Longitudinal monitoring revealed the dynamics pattern of IFN-gamma: early elevation predicted durable clinical benefit (DCB) (median PFS: not evaluable vs. 6.7 months in no-durable benefit [NDB]), while a persistent decrease post-cycle 4 indicated a risk of relapse (P = 0.028).
CONCLUSION: IFN-gamma emerges as a critical biomarker for prognostic assessment and therapeutic monitoring in advanced GC immunotherapy, and its composite model incorporating PD-L1 Combined Positive Score (CPS) demonstrated superior predictive efficacy, highlighting the necessity for validating additional biomarkers in future clinical studies.